Neuroderm Ltd (NDRM) Reaches $21.30 After 4.00% Down Move; Aratana Therapeutics Has 0.71 Sentiment

May 29, 2017 - By wolcottdaily

Aratana Therapeutics, Inc. is a pet therapeutics firm focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The company has market cap of $247.37 million. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. It currently has negative earnings. The Company’s lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation , appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA).

The stock of Neuroderm Ltd (NASDAQ:NDRM) is a huge mover today! The stock decreased 8.39% or $1.95 on May 26, reaching $21.3. About 243,839 shares traded or 25.97% up from the average. Neuroderm Ltd (NASDAQ:NDRM) has risen 27.60% since May 29, 2016 and is uptrending. It has outperformed by 10.90% the S&P500.The move comes after 5 months negative chart setup for the $513.95M company. It was reported on May, 29 by Barchart.com. We have $20.45 PT which if reached, will make NASDAQ:NDRM worth $20.56M less.

Among 5 analysts covering NeuroDerm (NASDAQ:NDRM), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. NeuroDerm had 9 analyst reports since August 6, 2015 according to SRatingsIntel. TH Capital maintained the stock with “Buy” rating in Thursday, August 6 report. As per Friday, August 14, the company rating was maintained by Jefferies. Raymond James initiated Neuroderm Ltd (NASDAQ:NDRM) on Wednesday, November 11 with “Outperform” rating. The stock of Neuroderm Ltd (NASDAQ:NDRM) has “Hold” rating given on Monday, August 10 by Zacks. The stock has “Perform” rating by Oppenheimer on Tuesday, March 7. The firm has “Buy” rating by Jefferies given on Friday, December 9. Roth Capital maintained the stock with “Buy” rating in Thursday, August 6 report. The stock of Neuroderm Ltd (NASDAQ:NDRM) has “Outperform” rating given on Tuesday, August 11 by Oppenheimer.

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The company has market cap of $513.95 million. The Firm is engaged in developing treatments for central nervous system disorders, primarily Parkinson’s disease, as well as other CNS diseases. It currently has negative earnings. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.

The stock decreased 0.34% or $0.02 on May 26, reaching $5.9. About 176,365 shares traded. Aratana Therapeutics Inc (PETX) has risen 1.52% since May 29, 2016 and is uptrending. It has underperformed by 15.18% the S&P500.